

## EFPIA Disclosure Code 2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom AbbVie works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, AbbVie hereby confirms that its disclosures of transfers of value (ToV) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

### **Disclosure quality**

AbbVie certifies that:

- Its disclosures are made in each country where reportable ToV have been made;
- Its disclosures include direct and indirect ToV, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

### **Methodology used for the collection and organisation of ToV is in line with the EFPIA Disclosure Code's requirements and applicable codes**

AbbVie certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to encourage individual disclosure for HCPs' and HCOs' Transfers of Value (each as defined in the EFPIA Disclosure Code).

**Aggregate disclosures are limited to Research and Development ToV and such ToV that cannot be disclosed on an individual basis for legal reasons**

AbbVie certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate sections.

**Ensuring compliance with Data Privacy Obligations**


AbbVie certifies that its disclosure complies with the applicable privacy and data protection law.

Date: May 22, 2019

Name of signatory: Carlos Alban

Position in the Company: Vice Chairman, Chief Commercial Officer

Signature:

A handwritten signature in black ink, appearing to read 'CARLOS ALBAN', is written over a horizontal line. Below this line is another horizontal line, possibly representing a separator or a second line of text.